3,688
edits
Malignant Hyperthermia: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 24: | Line 24: | ||
Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing. Anesthesiology. 2022 Jun 1;136(6):940-953. PMID: 35285867 | Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing. Anesthesiology. 2022 Jun 1;136(6):940-953. PMID: 35285867 | ||
[https://pubs.asahq.org/anesthesiology/article/136/6/940/135870/Referral-Indications-for-Malignant-Hyperthermia Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing] | |||
[https://www.bjanaesthesia.org/article/S0007-0912(22)00496-2/fulltext Functional analysis of RYR1 variants in patients with confirmed susceptibility to malignant hyperthermia] | [https://www.bjanaesthesia.org/article/S0007-0912(22)00496-2/fulltext Functional analysis of RYR1 variants in patients with confirmed susceptibility to malignant hyperthermia] | ||